Novozymes A/S (OTCMKTS:NVZMY) Shares Gap Down – Time to Sell?

Posted by Geri Gentry on Nov 9th, 2026

Novozymes A/S (OTCMKTS:NVZMY – Get Free Report)’s share price gapped down prior to trading on Monday. The stock had previously closed at $71.80, but opened at $67.85. Novozymes A/S shares last traded at $67.8480, with a volume of 906 shares changing hands.

Novozymes A/S Stock Performance

The company has a quick ratio of 1.04, a current ratio of 1.74 and a debt-to-equity ratio of 0.25. The business has a 50 day simple moving average of $67.50 and a two-hundred day simple moving average of $62.66. The firm has a market cap of $28.29 billion, a PE ratio of 40.38, a price-to-earnings-growth ratio of 3.09 and a beta of 0.86.

Novozymes A/S (OTCMKTS:NVZMY – Get Free Report) last released its earnings results on Thursday, November 5th. The biotechnology company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.74 by ($0.26). The business had revenue of $1.28 billion for the quarter, compared to the consensus estimate of $1.28 billion. Novozymes A/S had a return on equity of 6.56% and a net margin of 15.59%. As a group, equities research analysts forecast that Novozymes A/S will post 2.45 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Novozymes A/S stock. Elefante Mark B boosted its stake in shares of Novozymes A/S (OTCMKTS:NVZMY – Free Report) by 73.5% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,900 shares of the biotechnology company’s stock after buying an additional 2,500 shares during the quarter. Elefante Mark B’s holdings in Novozymes A/S were worth $371,000 as of its most recent SEC filing. Institutional investors own 0.03% of the company’s stock.

Novozymes A/S Company Profile

(Get Free Report)

Novozymes A/S was a Denmark-based biotechnology company that developed and produced enzymes and microorganisms for industrial and consumer applications. Its solutions were used in areas including household care, food and beverages, agriculture, animal health and bioenergy.

The company’s products included enzymes used in detergents, baking, brewing and biofuel production, as well as microbial solutions for agricultural and other industrial processes. Novozymes served customers in markets around the world.

In January 2024, Novozymes merged with Danish bioscience company Chr.